Oculis Holding AG (OCS) EBT (2022 - 2026)

Oculis Holding AG's (OCS) quarterly EBT came in at -$37.0 million in Q1 2026, little changed year-on-year from -$37.0 million in Q1 2025, and down 24.7% quarter-over-quarter from -$29.6 million in Q4 2025.

Oculis Holding AG (OCS) EBT (2022 - 2026) Analysis & Trends

Oculis Holding AG's EBT history runs 5 years deep, the most recent figure standing at -$37.0 million for Q1 2026.

  • On a quarterly basis, EBT changed 0.1% year-over-year to -$37.0 million in Q1 2026; TTM through Mar 2026 was -$21.2 billion, a 9.51% increase from a year earlier, with the FY2025 full-year figure at -$119.6 million, down 22.41% from the prior year.
  • EBT retreated to -$37.0 million in Q1 2026 per OCS's latest filing, from -$29.6 million in the prior quarter.
  • Across five years, EBT topped out at -$9.5 million in Q4 2022 and bottomed at -$23.3 billion in Q3 2024.
  • The 5-year median for EBT is -$26.3 million (2025), against an average of -$2.8 billion.
  • Biggest YoY gain for EBT was 62.91% in 2024; the steepest drop was 117219.62% in 2024.
  • Year by year, EBT stood at -$9.5 million in 2022, then tumbled by 47.75% to -$14.1 million in 2023, then slumped by 133.82% to -$33.0 million in 2024, then rose by 10.11% to -$29.6 million in 2025, then declined by 24.7% to -$37.0 million in 2026.
  • Per Business Quant, the three latest OCS EBT figures stand at -$37.0 million (Q1 2026), -$29.6 million (Q4 2025), and -$21.1 billion (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -36.97 Mn
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -15.31 Mn
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 259.22 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 1.25 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 831.20 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -26.94 Mn
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 438.00 Mn
9 Revolution Medicines 37.37 Bn 37.37 Bn - -453.82 Mn
10 Alnylam Pharmaceuticals 36.08 Bn 33.07 Bn 959.66 Mn 221.65 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -36.97 Mn
Dec 31, 2025 -29.65 Mn
Sep 30, 2025 -21.05 Bn
Jun 30, 2025 -30.68 Mn
Mar 31, 2025 -36.93 Mn
Dec 31, 2024 -32.98 Mn
Sep 30, 2024 -23.28 Bn
Jun 30, 2024 -23.01 Mn
Mar 31, 2024 -18.40 Mn
Dec 31, 2023 -14.11 Mn
Sep 30, 2023 -19.85 Mn
Jun 30, 2023 -14.19 Mn
Mar 31, 2023 -49.62 Mn
Dec 31, 2022 -9.55 Mn
Sep 30, 2022 -10.30 Mn
Jun 30, 2022 -12.77 Mn